- Home
- IH vs CHRS Comparison
IH vs CHRS Comparison
Compare IH & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IH
- CHRS
- Stock Information
- Founded
- IH 1996
- CHRS 2010
- Country
- IH China
- CHRS United States
- Employees
- IH N/A
- CHRS N/A
- Industry
- IH Other Consumer Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IH Real Estate
- CHRS Health Care
- Exchange
- IH Nasdaq
- CHRS Nasdaq
- Market Cap
- IH 123.1M
- CHRS 112.5M
- IPO Year
- IH 2020
- CHRS 2014
- Fundamental
- Price
- IH $2.38
- CHRS $0.78
- Analyst Decision
- IH
- CHRS Buy
- Analyst Count
- IH 0
- CHRS 3
- Target Price
- IH N/A
- CHRS $4.68
- AVG Volume (30 Days)
- IH 10.6K
- CHRS 1.5M
- Earning Date
- IH 06-27-2025
- CHRS 05-12-2025
- Dividend Yield
- IH 3.57%
- CHRS N/A
- EPS Growth
- IH N/A
- CHRS N/A
- EPS
- IH 0.25
- CHRS N/A
- Revenue
- IH $126,344,481.00
- CHRS $272,251,000.00
- Revenue This Year
- IH $39.02
- CHRS N/A
- Revenue Next Year
- IH N/A
- CHRS $19.78
- P/E Ratio
- IH $9.65
- CHRS $1.83
- Revenue Growth
- IH N/A
- CHRS 19.87
- 52 Week Low
- IH $1.47
- CHRS $0.66
- 52 Week High
- IH $3.18
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- IH 56.54
- CHRS 40.90
- Support Level
- IH $2.25
- CHRS $0.74
- Resistance Level
- IH $2.39
- CHRS $0.82
- Average True Range (ATR)
- IH 0.12
- CHRS 0.07
- MACD
- IH -0.00
- CHRS -0.00
- Stochastic Oscillator
- IH 71.54
- CHRS 19.71
About IH iHuman Inc.
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.